Caelyx™ in malignant mesothelioma:: A phase II EORTC study

被引:42
作者
Baas, P
van Meerbeeck, J
Groen, H
Schouwink, H
Burgers, S
Daamen, S
Giaccone, G
机构
[1] Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands
[2] Univ Hosp, Rotterdam, Netherlands
[3] Acad Hosp, Groningen, Netherlands
[4] EORTC Data Ctr, Amsterdam, Netherlands
[5] Free Univ Amsterdam Hosp, Amsterdam, Netherlands
关键词
Caelyx; doxorubicin; liposomal doxorubicin; mesothelioma; phase II;
D O I
10.1023/A:1008346925273
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The use of doxorubicin has shown some activity in malignant mesothelioma but prolonged administration is hampered by cardiotoxicity. Caelyx(TM), a new liposomal and pegylated form of doxorubicin has shown a better pharmacokinetic and toxic profile then doxorubicin. In a phase II study, the efficacy and toxicity of Caelyx(TM) was tested in previously untreated patients with malignant pleural mesothelioma. Patients and methods: Thirty-three patients who had measurable or evaluable histologically confirmed malignant pleural mesothelioma were included in the study. Caelyx(TM) (45 mg/m(2)) was given i.v. on outpatient base every four weeks for nine cycles or till progression or unacceptable toxicity occurred. Results: Of the 33 patients, 32 were evaluable for toxicity and 31 for response. Two patients had a partial response (6%, 95% confidence interval: 0.2%-20.2%). The median survival was 13 months. Forty percent of the patients received > 6 cycles. Toxicity was mild with palmar plantar erythrodysesthesia being most pronounced (62% grade 1-2, 6% grade 3) and of limited duration. Ten percent of patients had grade 3 anemia and 3% grade 3 thrombocytopenia. Two patients (6%) had grade 3 or 4 cardiac toxicity, which was not drug related. Conclusion: At the prescribed dose, single agent Caelyx(TM) is well tolerated but its activity in chemotherapy-naive mesothelioma patients does not warrant further investigation as a single agent.
引用
收藏
页码:697 / 700
页数:4
相关论文
共 19 条
[1]  
AISNER J, 1995, CHEST, V108, P1122
[2]   Malignant pleural mesothelioma [J].
Baas, P ;
Schouwink, H ;
Zoetmulder, FAN .
ANNALS OF ONCOLOGY, 1998, 9 (02) :139-149
[3]   THE TREATMENT OF MALIGNANT MESOTHELIOMA OF THE PLEURA - REVIEW OF A 5-YEAR EXPERIENCE, WITH SPECIAL REFERENCE TO RADIOTHERAPY [J].
BALL, DL ;
CRUICKSHANK, DG .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (01) :4-9
[4]   A phase II study of Doxil (liposomal doxorubicin): Lack of activity in poor prognosis soft tissue sarcomas [J].
Garcia, AA ;
Kempf, RA ;
Rogers, M ;
Muggia, FM .
ANNALS OF ONCOLOGY, 1998, 9 (10) :1131-1133
[5]  
LERNER HJ, 1983, CANCER, V52, P1981, DOI 10.1002/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO
[6]  
2-P
[7]  
MATTSON K, 1992, JCO, V10, P825
[8]   Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation [J].
Muggia, FM ;
Hainsworth, JD ;
Jeffers, S ;
Miller, P ;
Groshen, S ;
Tan, M ;
Roman, L ;
Uziely, B ;
Muderspach, L ;
Garcia, A ;
Burnett, A ;
Greco, FA ;
Morrow, CP ;
Paradiso, LJ ;
Liang, LJ .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :987-993
[9]   Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy [J].
Northfelt, DW ;
Dezube, BJ ;
Thommes, JA ;
Levine, R ;
VonRoenn, JH ;
Dosik, GM ;
Rios, A ;
Krown, SE ;
DuMond, C ;
Mamelok, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :653-659
[10]  
POSTMUS PE, ORAL ETOPOSIDE MALIG